干燥综合征（Sjo^egren’s syndrome）口干治疗进展

早在1933年HenrickSj6gren对本病就有报道。故命名为Sjo^egren syndrome，简称SS，分为原发性干燥综合征(Pss)和继发性干燥综合征(Sss)。原发性干燥综合征主要是腺泡间局部管周围单核细胞浸润和腺泡萎缩，使唾液流速率和唾液成分发生改变的全身性自身免疫性疾病。继发性主要来     

干燥综合征的靶向治疗进展

干燥综合征（SS）是一种以外分泌腺受累为主,可累及全身系统的自身免疫性疾病。患者常因口干、眼干、疲劳、疼痛、脏器受累等,严重影响生活质量。近年来,随着人们对干燥综合征发病机制的深入认识,多种靶向药物正在研发中,有望用于治疗此类患者。     

超声在干燥综合征诊治中的应用进展

干燥综合征是一种主要累及外分泌腺体的慢性炎症性自身免疫性疾病。临床常用的检查方法包括涎腺同位素检查、唇腺活检和X线腮腺造影,但均为有创检查。超声作为一种重要的无创性影像工具,在干燥综合征的诊断和病情评估中发挥着越来越重要的作用。本文就超声在干燥综合征诊治中的应用进展进行综述。     

干燥综合征的治疗现状及进展

干燥综合征(SS)是一组高度异质性的系统性自身免疫病,以口干眼干为特征,并常伴有腺体外的器官受 累。目前对于SS尚无标准的治疗方案,局部治疗以替代治疗为主,当有重要脏器受累时则需要全身应用糖皮质激素 和免疫抑制剂。随着生物制剂在类风湿关节炎的治疗上获得极大成功,以B细胞清除为主的靶向治疗越来越多地被 用来治疗SS,也显示出良好的疗效和应用前景。本文将重点回顾SS规范化治疗现状和近年来在治疗学上取得的进 展,以期能够指导SS治疗的临床实践。     

新风胶囊治疗干燥综合征临床观察

目的:观察新风胶囊(XFC)对干燥综合征患者的疗效和生活质量的影响。方法:将38例干燥综合征患者随机分为2组,各19例,治疗组采用XFC,对照组采用白芍总苷胶囊(TGP),观察2组治疗前后生活质量积分、抑郁自评量表积分(SDS)、中医症状积分、实验室指标等变化。结果:①中医临床疗效评价发现治疗组和对照组的有效率分别为89.47%和68.42%,差异有统计学意义(P<0.05);②2组治疗前生活质量各维度积分(SF-36)、抑郁评分(SDS)差异无统计学意义,治疗组治疗后的SF-36各维度评分高于对照组,SDS评分低于对照组,差异有统计学意义(P<0.05);③治疗组在改善实验室指标、中医症候积分方面优于对照组(P<0.05)。结论:新风胶囊用于治疗干燥综合征具有很好的临床疗效,在提高患者生活质量及改善抑郁情绪、中医症候及实验室指标方面优于对照组。     

原发性干燥综合征诊治进展

干燥综合征（Sjogren’s Syndrome，SS）是一种以侵犯唾液腺和泪腺等外分泌腺、具有高度淋巴细胞浸润为特征的系统性自身免疫病。口、眼干燥为常见的症状，常出现皮肤、肺、肝、肾、神经及血管等多系统损害。本病分为原发性（pSS）和继发性两类。本文重点介绍了pSS的发病机制、病理改变、临床表现、实验室检查、诊断标准及治疗最新进展。     

原发性干燥综合征疲劳的机制与治疗进展

原发性干燥综合征是一种主要侵犯泪腺、唾液腺等外分泌腺的慢性系统性自身免疫性疾病,除了表现为口干、眼干外,通常还伴有明显的疲劳症状,严重影响患者的生活质量.疲劳常与抑郁、疼痛、嗜睡相互影响.肾小管性酸中毒、热休克蛋白和遗传变异是疲劳较为明确的机制,目前还缺乏有效的药物治疗,有氧运动能一定程度缓解疲劳.     

中医药治疗干燥综合征临床研究进展

干燥综合征(SS)是以淋巴细胞或浆细胞在唾液腺和泪腺浸润后导致腺体分泌不足为特征,眼、口腔干燥为主要临床表现的自身免疫性疚病,同时还可累及肾、肺、甲状腺和肝等多种器官.     

干燥综合征合并肺间质病变的临床诊断治疗进展

正干燥综合征(Sj觟gren's syndrome, SS)是主要累及外分泌腺的慢性自身免疫病,又被称作自身免疫性外分泌腺上皮炎或自身免疫性外分泌腺病。患者有泪腺及唾液腺的功能减低,出现特征性的口干、眼干、猖獗龋齿、腮腺肿大等临床表现。干燥综合征可分为原发性干燥综合征(primary Sj觟-gren's syndrome,pSS)和继发性干燥综合征(secondary Sj觟-     

咽瘘的治疗与护理进展

咽瘘是下咽癌及喉癌术后常见的并发症,1996年以来国 内外文献报道它的发生率3.2%～38.6%不等[1-2]。随着手 术、抗感染、预防等治疗和护理方法的改进,咽瘘的发生已大 大减少,总结2000～2003年我科咽喉恶性肿瘤咽瘘的发生率 为4.85%,且均见于下咽癌颈淋巴转移,且大范围手术切除 的患者。它的发生、发展关系到患者的生活质量与生命质量, 如何更好地治疗和护理这类患者,查阅文献并结合我科的实 践体会综述如下。 1　咽瘘的定义 咽瘘是指唾液贮积皮下或切口下组织,形成脓腔破溃至 皮肤或切口外,即下咽与皮肤相通。使下咽或食管腔与皮肤 相…     

Burning mouth syndrome: Identification, diagnosis, and treatment

Purpose: To provide an overview of burning mouth syndrome (BMS), describe the role of the clinician when a patient presents with the burning mouth complaint, offer guidance in differentiating the cause of the complaint, and identify potential treatment options for the patient suffering from BMS.
Data sources: A search of MD Consult, Medline, and EBSCO Host Research Databases with the terms "burning mouth" and "BMS."
Conclusions: BMS is a common, chronic disorder of unknown etiology with no underlying or systemic causes or oral signs identified. It affects more than 1 million people in the United States, predominantly postmenopausal women. Despite the common nature of the disorder, it is often misunderstood. Palliative treatment, education, and support should be offered to the patient with idiopathic BMS. A variety of treatment options exist, including benzodiazepines, tricyclic antidepressants, anticonvulsants, alpha-lipoic acid, topical capsaicin, and cognitive therapy can be added to the medication regimen for greater benefit.
Implications for practice: The role of the clinician is to obtain a meticulous history and physical examination of the patient, order relevant diagnostic tests, and rule out treatable conditions that may be causing the burning mouth symptom. If secondary causes of BMS are ruled out, the clinician should present treatment options to the patient and consider referral to specialists as necessary. A combination of medications may be more effective than a single medication.     

Burning mouth syndrome

Burning mouth syndrome is characterized by a burning sensation in the tongue or other oral sites, usually in the absence of clinical and laboratory findings. Affected patients often present with multiple oral complaints, including burning, dryness and taste alterations. Burning mouth complaints are reported more often in women, especially after menopause. Typically, patients awaken without pain but note increasing symptoms through the day and into the evening. Conditions that have been reported in association with burning mouth syndrome include chronic anxiety or depression, various nutritional deficiencies, type 2 diabetes (formerly known as non-insulin-dependent diabetes) and changes in salivary function. However, these conditions have not been consistently linked with the syndrome, and their treatment has had little impact on burning mouth symptoms. Recent studies have pointed to dysfunction of several cranial nerves associated with taste sensation as a possible cause of burning mouth syndrome. Given in low dosages, benzodiazepines, tricyclic antidepressants or anticonvulsants may be effective in patients with burning mouth syndrome. Topical capsaicin has been used in some patients.     

Burning mouth syndrome

Burning mouth syndrome (BMS) is a chronic disease characterized by burning of the oral mucosa associated with a sensation of dry mouth and/or taste alterations. BMS occurs more frequently among postmenopausal women. The pathophysiology of the disease is still unknown, and evidence is conflicting; although some studies suggest a central origin, others point to a peripheral neuropathic origin. The efficacy of some medications in the treatment of BMS suggests that the dopaminergic system may be involved.     

Burning mouth syndrome responsive to pramipexol

Burning mouth syndrome (BMS) is characterized by burning discomfort or pain in otherwise normal oral mucosa. It is usually refractory. Treatment modalities are scarce. Herein we report one case of primary disabling BMS, previously refractory to multiple regimens, with complete and persistent improvement with pramipexol, a nonergot dopamine agonist which has high selectivity for dopaminergic D2 receptors. We discuss potential pathophysiological implications of our findings.